Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension

Scandinavian Cardiovascular Journal

Volumn 48, Issue 4, 2014, Pages 223-233

  Kylhammar, David ^a,b   Persson, Liselotte ^b   Hesselstrand, Roger ^a,b   Rådegran, Göran ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Combination therapy; Human; Prognosis; Pulmonary arterial hypertension; Survival

Indexed keywords

AMBRISENTAN; BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL; TREPROSTINIL; ANTIHYPERTENSIVE AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; DRUG DOSE ESCALATION; FEMALE; HEART RIGHT ATRIUM PRESSURE; HEREDITARY PULMONARY ARTERIAL HYPERTENSION; HUMAN; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING; AGED; ARTERIAL PRESSURE; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECTS; EXERCISE TOLERANCE; FAMILIAL PRIMARY PULMONARY HYPERTENSION; GENETIC PREDISPOSITION; GENETICS; HEART ATRIUM FUNCTION; HEART ATRIUM PRESSURE; HYPERTENSION, PULMONARY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PULMONARY ARTERY; SWEDEN; TIME; VASCULAR RESISTANCE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; ATRIAL FUNCTION, RIGHT; ATRIAL PRESSURE; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY ARTERY; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84904619344     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2014.931595     Document Type: Article

References (35)

1. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004; 43: 25S-32.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997; 336: 111-7.
3. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiéry J-L, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009; 34: 1219-63.
4. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54: S43-54.
5. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012; 142: 448-56.
6. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36: 549-55.
7. Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol. 2011; 40: 127-32.
8. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115: 343-9.
9. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009; 30: 394-403.
10. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al. Macitentan and Morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369: 809-18.
11. Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369: 330-40.
12. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327: 76-81.
13. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111: 3105-11.
14. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012; 39: 589-96.
15. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoproste-nol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004; 24: 353-9.
16. Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant. 2012; 31: 150-8.
17. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166: 111-7.
18. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001; 358: 1119-23.
19. Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY-study): a double-blind, randomised controlled trial. Lancet. 2008; 371: 2093-100.
20. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch DB, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353: 2148-57.
21. Actelion. Actelion provides an update on the bosentan study-COMPASS-2 [Internet]. Available from: http://www.actelion.com/en/our-company/news-and- events/index. page?newsId= 1769001 [updated March 17, 2014; cited 2014 April 17].
22. Venitz J, Zack J, Gillies H, Allard M, Regnault J, Dufton C. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012; 52: 1784-805.
23. GlaxoSmithKline. AMBITION: A randomized, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) [Internet]. 2010-[updated April 15 2014]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01178073.
24. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122: 156-63.
25. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010; 122: 164-72.
26. Kane GC, Maradit-Kremers H, Slusser JP, Scott CG, Frantz RP, McGoon MD. Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension. Chest. 2011; 139: 1285-93.
27. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40: 780-8.
28. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27: 589-95.
29. Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012; 60: 1192-201.
30. Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012; 126: 349-56.
31. Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013; 143: 315-23.
32. Galiè N, Channick RN, Delcroix M, Ghofrani HA, Jansa P, Le Brun F-O, et al. Sustained effect of macitentan, a novel oral endothelin receptor antagonist, on exercise capacity and the association of its measure with long-term outcomes in pulmonary arterial hypertension. Eur Heart J. 2013; 34(Abstract supplement): 186.
33. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010; 35: 1079-87.
34. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106: 1477-82.
35. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, et al. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010; 181: 1106-13.